2024-511426-31-00CompletedPhase 1
A prospective, single-centre, randomised, double-blind, placebo-controlled, phase I, First-In-Human (FIH) trial evaluating the safety and tolerability of single and multiple ascending oral doses of IRL757 in healthy volunteers.
Integrative Research Laboratories Sweden AB1 site in 1 country82 target enrollmentStarted: May 3, 2024Last updated:
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Enrollment
- 82
- Locations
- 1
Study Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 64 years (18-64 Years)
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Chief Medical Officer
Scientific
Integrative Research Laboratories Sweden AB
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
A prospective, single-centre, randomised, double-blind, placebo-controlled trial to assess the analgesic effects of one-week treatment with anti-tumour necrotising factor (TNF) in patients with lower back and leg paiISRCTN14943354Record Provided by the NHSTCT Register - 2006 Update - Department of Health (UK)40
Active, not recruiting
Not Applicable
A prospective, single centre, randomised, double-blind, placebo controlled trial to assess the analgesic effects of one week treatment with anti-TNF in patients with lower back and leg pain. - Pilot study of anti-TNF use in lower back and leg pain patientswower back and leg painEUCTR2005-003722-26-GBBarts and the London NHS Trust40
Active, not recruiting
Phase 1
A single-center, prospective, randomized, double-blind, intra-patient (left-to-right) placebo-controlled, pilot study to assess the efficacy and safety of a betamethasone valerate 0.1% medicated plaster in the treatment of finger nail psoriasisail PsoriasisEUCTR2014-000291-25-ITIBSA Institut Biochimique S.A.30
Active, not recruiting
Phase 1
A single center randomised placebo controlled study to test a novel topical formulation containing Niclosamide, an antibiotic.AntibioTx has developed a topical product (ATx201) for treatment of infected eczema and infected atopic dermatitis. These infections are predominantly caused by Staphyllococcus aureus and various species of Streptococcus. Treatment of these infections is plagued by inactivity of or resistance towards the main topical antibiotics (fucidic acid, mupirocin and retapamulin).MedDRA version: 20.0Level: HLTClassification code 10040788Term: Skin and subcutaneous tissue bacterial infectionsSystem Organ Class: 100000004858EUCTR2016-003501-33-ATAntibioTx ApS76
Completed
Not Applicable
A prospective, single-center randomised double-blinded parallel-group comparison study of the postoperative pain control efficacy of a sciatic nerve block versus combined local anaesthetic infiltration and continuous femoral nerve block after total knee arthroplastyDegenerative arthritisJPRN-UMIN000013364Saitama City Hospital34